Is the Genetic Background of Co-Stimulatory CD28/CTLA-4 Pathway the Risk Factor for Prostate Cancer?

Karabon, Lidia; Tupikowski, Krzysztof; Tomkiewicz, Anna; Partyka, Anna; Pawlak, Edyta; Wojciechowski, Adam; Kołodziej, Anna; Dembowski, Janusz; Zdrojowy, Romuald; Frydecka, Irena

doi:10.1007/s12253-016-0180-4

Cited by 6 publications

(5 citation statements)

References 56 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The literature search found 788 documents with 132 studies were excluded after duplicates were removed, and 591 studies were excluded after reviewing the retrieved literature’s titles and abstracts. The full text of 65 remaining citations was screened, and finally 19 studies including 11 811 patients were included in this meta-analysis [9,12–15,18–31]. The flow chart of the meta-analysis is represented in Figure 1.…”

Section: Resultsmentioning

confidence: 99%

“…The basic information and quality evaluation (NOS) results included in the study are shown in Table 1. The included studies looked at cancer patients in Asia (n=6) [9,12,13,21,29,30] and Caucasians (n=13) [14,15,18–20,22–28,31]. In addition, in terms of cancer types, leukemia (n=2) [12,26], breast cancer (n=3) [9,13,15], colorectal cancer (n=3) [20,27,30)], cervical cancer (n=4) [21–23,28], and other cancers (prostate cancer, gastric cancer, renal cell carcinoma, non-small-cell lung cancer, melanoma, myeloma, lymphoma) were included in studies [4,9,14,18,25,29,31].…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Association Between the CD28 c.17 +3 T>C Polymorphism (rs3116496) and Cancer Risk: An Updated Meta-Analysis

Zeng

Lai

2019

Med Sci Monit

View full text Add to dashboard Cite

BackgroundNumerous studies have been conducted on whether CD28 rs3116496 polymorphism affected cancer susceptibility, and these findings have been controversial. Thus, the purpose of this study was to assess the relationship between rs3116496 and susceptibility to cancer.Material/MethodsThe research published as of October 25, 2018 were comprehensively searched in PubMed, Embase, Cochrane Library and Chinese Wanfang database, CNKI, CBM. Statistical calculations performed using Stata12.0.ResultsOverall analyses found that rs3116496 was a risk factor for cancer (C versus T, OR=1.14, 95% CI: 1.01–1.29, PH=0.003), and the heterogeneity was moderate (I2=53.3%). In subgroup analysis results by cancer types, the analysis showed that rs3116496 was a risk factor for breast cancer and leukemia. In the subgroup analysis by ethnicity, rs3116496 was a risk factor for cancer in the Asian population. After PHWE<0.05 was deleted, the analysis showed that rs3116496 might be related to the increased risk of colorectal cancer.ConclusionsOur meta-analysis confirmed that rs3116496 was significantly related to cancer risk, especially in an Asian population, and was strongly correlated with the increased risk of breast cancer, leukemia and colorectal cancer.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Association Between the CD28 c.17 +3 T>C Polymorphism (rs3116496) and Cancer Risk: An Updated Meta-Analysis

Zeng

Lai

2019

Med Sci Monit

View full text Add to dashboard Cite

show abstract

“…These researchers reported that the CTLA-4c.49A>G and CTLA-4g.319C>T SNPs might be considered as low risk susceptibility locus for PCa. 22 The limitation of the study is it cannot find the serum PSA level of control group.…”

Section: Discussionmentioning

confidence: 96%

“…In another study by Karabon et al, 22 SNPs in CTLA-4 and CD28 genes were genotyped in 301 prostate cancer (PCa) patients and 301 controls. These researchers revealed that the frequency of alleles, and genotypes in the CTLA-4 and CD28 genes did not significantly differ between the PCa patients and the controls.…”

Section: Discussionmentioning

confidence: 99%

CTLA-4 Gene +49 A/G Polymorphism in Prostate Cancer Patients in Turkish Population

Diler¹

2017

ACP

View full text Add to dashboard Cite

Background: Cytotoxic T-lymphocyte antigen 4 (CTLA-4), the T cell surface antigen is expressed during activation. Prostate cancer (PCa) is one of the most common cancers in Western population and its rate is increasing in the Eastern World. The aim of this study was to evaluate cytotoxic T lymphocyte associated antigen-4 (CTLA-4) gene+49A/G polymorphisms in prostate cancer patients. Material and methods:This study included 119 (mean age: 68.94±8.38 years) healthy controls and 62 (mean age: 72.83±7.60 years) patients with prostate cancer. The CTLA-4 gene+49A/G (rs231775) gene regions were amplified using polymerase chain reaction (PCR), detected by restriction fragment length polymorphism (RFLP).

show abstract

“…The authors observed overrepresentation of the carriers of the CTLA-4c.49*A allele and the carriers of the CTLA-4c.-319*T allele in patients as compared to controls. Moreover, the individuals possessing both susceptibility alleles CTLA-4c.49*A and CTLA-4c.-319*T had 1.78-fold increased risk of PC than individuals with protective G/G and C/C genotypes, respectively ( 138 ).…”

Section: Cytotoxic T Lymphocyte-associated Antigen-4mentioning

confidence: 99%

Immune Checkpoint Molecules—Inherited Variations as Markers for Cancer Risk

2021

Self Cite

View full text Add to dashboard Cite

In recent years, immunotherapy has been revolutionized by a new approach that works by blocking receptors called immune checkpoints (IC). These molecules play a key role in maintaining immune homeostasis, mainly by suppressing the immune response and by preventing its overactivation. Since inhibition of the immune response by IC can be used by cancer to avoid recognition and destruction by immune system, blocking them enhances the anti-tumor response. This therapeutic approach has brought spectacular clinical effects. The ICs present heterogeneous expression patterns on immune cells, which may affect the effectiveness of immunotherapy. The inherited genetic variants in regulatory regions of ICs genes can be considered as potential factors responsible for observed inter-individual differences in ICs expression levels on immune cells. Additionally, polymorphism located in exons may introduce changes to ICs amino acid sequences with potential impact on functional properties of these molecules. Since genetic variants may affect both expression and structure of ICs, they are considered as risk factors of cancer development. Inherited genetic markers such as SNPs may also be useful in stratification patients into groups which will benefit from particular immunotherapy. In this review, we have comprehensively summarized the current understanding of the relationship between inherited variations of CTLA-4, PDCD1, PD-L1, BTLA, TIM-3, and LAG-3 genes in order to select SNPs which can be used as predictive biomarkers in personalized evaluation of cancer risk development and outcomes as well as possible response to immunotherapy.

show abstract

Is the Genetic Background of Co-Stimulatory CD28/CTLA-4 Pathway the Risk Factor for Prostate Cancer?

Cited by 6 publications

References 56 publications

Association Between the CD28 c.17 +3 T>C Polymorphism (rs3116496) and Cancer Risk: An Updated Meta-Analysis

Association Between the CD28 c.17 +3 T>C Polymorphism (rs3116496) and Cancer Risk: An Updated Meta-Analysis

CTLA-4 Gene +49 A/G Polymorphism in Prostate Cancer Patients in Turkish Population

Immune Checkpoint Molecules—Inherited Variations as Markers for Cancer Risk

Contact Info

Product

Resources

About